232 related articles for article (PubMed ID: 31578782)
1. Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer.
Lu RM; Chiu CY; Liu IJ; Chang YL; Liu YJ; Wu HC
Cancer Sci; 2019 Dec; 110(12):3773-3787. PubMed ID: 31578782
[TBL] [Abstract][Full Text] [Related]
2. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J
Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891
[TBL] [Abstract][Full Text] [Related]
3. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L
Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327
[TBL] [Abstract][Full Text] [Related]
4. A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity.
Chen Z; Xie W; Acheampong DO; Xu M; He H; Yang M; Li C; Luo C; Wang M; Zhang J
Cancer Biol Ther; 2016; 17(2):139-50. PubMed ID: 26671532
[TBL] [Abstract][Full Text] [Related]
5. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
6. A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.
Liu Y; He Y; Yang F; Cong X; Wang J; Peng S; Gao D; Wang W; Lan L; Ying X; Liu M; Chen Y; Yi Z
Sci China Life Sci; 2017 Feb; 60(2):202-214. PubMed ID: 28194552
[TBL] [Abstract][Full Text] [Related]
7. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
Wicki A; Rochlitz C; Orleth A; Ritschard R; Albrecht I; Herrmann R; Christofori G; Mamot C
Clin Cancer Res; 2012 Jan; 18(2):454-64. PubMed ID: 22065082
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2.
Zhang H; Li Y; Li H; Bassi R; Jimenez X; Witte L; Bohlen P; Hicklin D; Zhu Z
Leuk Lymphoma; 2004 Sep; 45(9):1887-97. PubMed ID: 15223651
[TBL] [Abstract][Full Text] [Related]
9. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
Zhu Z; Hattori K; Zhang H; Jimenez X; Ludwig DL; Dias S; Kussie P; Koo H; Kim HJ; Lu D; Liu M; Tejada R; Friedrich M; Bohlen P; Witte L; Rafii S
Leukemia; 2003 Mar; 17(3):604-11. PubMed ID: 12646950
[TBL] [Abstract][Full Text] [Related]
11. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
Gao J; Hu H; Wang X
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
[TBL] [Abstract][Full Text] [Related]
12. Development of humanized rabbit monoclonal antibodies against vascular endothelial growth factor receptor 2 with potential antitumor effects.
Yu Y; Lee P; Ke Y; Zhang Y; Chen J; Dai J; Li M; Zhu W; Yu GL
Biochem Biophys Res Commun; 2013 Jul; 436(3):543-50. PubMed ID: 23770369
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
Lin YC; Liu CY; Kannagi R; Yang RB
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
[TBL] [Abstract][Full Text] [Related]
14. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
[TBL] [Abstract][Full Text] [Related]
15. Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.
Lai YD; Wu YY; Tsai YJ; Tsai YS; Lin YY; Lai SL; Huang CY; Lok YY; Hu CY; Lai JS
Int J Mol Sci; 2016 Feb; 17(2):214. PubMed ID: 26861297
[TBL] [Abstract][Full Text] [Related]
16. NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
Yu P; Ye L; Wang H; Du G; Zhang J; Zuo Y; Zhang J; Tian J
PLoS One; 2014; 9(12):e115041. PubMed ID: 25551444
[TBL] [Abstract][Full Text] [Related]
17. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
18. Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway.
Xu X; Wu L; Zhou X; Zhou N; Zhuang Q; Yang J; Dai J; Wang H; Chen S; Mao W
Microvasc Res; 2017 May; 111():25-31. PubMed ID: 28040437
[TBL] [Abstract][Full Text] [Related]
19. Suppression of angiogenesis and tumor growth by recombinant T4 phages displaying extracellular domain of vascular endothelial growth factor receptor 2.
Zuo S; Dai G; Wang L; Wen Y; Huang Z; Yang W; Ma W; Ren X
Arch Virol; 2019 Jan; 164(1):69-82. PubMed ID: 30259141
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
